- United States
- /
- Medical Equipment
- /
- NasdaqGS:IDXX
Did Rising International Diagnostics and inVue Dx Adoption Just Shift IDEXX Laboratories' (IDXX) Growth Narrative?

Reviewed by Sasha Jovanovic
- In recent months, IDEXX Laboratories reported strong growth in its Companion Animal Group Diagnostics segment, with international recurring revenues rising and a successful rollout of the inVue Dx analyzer leading to an increased full-year installation target.
- The company's focus on expanding cloud-based software solutions and digital platform acquisitions has further enhanced its global commercial capabilities and reinforced its leadership in veterinary point-of-care testing.
- We'll examine how the momentum in international diagnostic revenue and instrument adoption impacts IDEXX Laboratories' long-term growth narrative.
Find companies with promising cash flow potential yet trading below their fair value.
IDEXX Laboratories Investment Narrative Recap
To own shares in IDEXX Laboratories, an investor needs to believe in the continued global expansion of advanced veterinary diagnostics, particularly as the company pushes adoption of new platforms like inVue Dx and cloud-based solutions. The recent momentum in international recurring revenues and instrument placements supports the key short-term catalyst, strong growth in the Companion Animal Group Diagnostics segment. Importantly, the latest results do not fully offset the ongoing risk from softening U.S. clinical visit trends, which could limit recurring revenue growth if sustained.
The most relevant recent announcement is IDEXX’s upward revision of full-year revenue and earnings guidance after Q2 2025. This outlook upgrade was driven by robust international demand and the rollout of the inVue Dx analyzer, aligning squarely with the main catalyst of increased diagnostic utilization globally. As these trends progress, they reinforce IDEXX's ability to drive recurring revenues from both consumables and software solutions.
Yet, for investors, it’s equally important to be mindful that softening U.S. clinical visit growth remains a risk, particularly if it continues to pressure...
Read the full narrative on IDEXX Laboratories (it's free!)
IDEXX Laboratories' narrative projects $5.2 billion in revenue and $1.3 billion in earnings by 2028. This requires 8.8% yearly revenue growth and a $314 million earnings increase from the current $985.7 million.
Uncover how IDEXX Laboratories' forecasts yield a $695.09 fair value, a 10% upside to its current price.
Exploring Other Perspectives
Three perspectives from the Simply Wall St Community estimate IDEXX’s fair value between US$468 and US$695 per share. While international segment gains are supporting recent optimism, you can see how investor opinions differ and explore several alternative viewpoints here.
Explore 3 other fair value estimates on IDEXX Laboratories - why the stock might be worth 26% less than the current price!
Build Your Own IDEXX Laboratories Narrative
Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.
- A great starting point for your IDEXX Laboratories research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- Our free IDEXX Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IDEXX Laboratories' overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
- Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
- AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- The end of cancer? These 28 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqGS:IDXX
IDEXX Laboratories
Develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally.
Outstanding track record with excellent balance sheet.
Similar Companies
Market Insights
Community Narratives


